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Abstract
Background. Treatment modalities for hepatic metastases from neuroendocrine tumours (NETs) include surgery,
somatostatin analogues and arterial embolization. The aims of this study were to evaluate the outcome of patients
following surgery and to identify prognostic predictors of recurrent disease. Patients and methods. This was a retrospective
clinico-pathological analysis of patients managed with hepatic NET metastases over a 13-year period (January 1994 to
December 2006). Results. Eighteen patients with hepatic metastases from NET were identified with a median age of
53 years (range 3175). The localization of the primary tumour was the terminal ileum (n8), pancreas (n7),
appendix (n2) or duodenum (n1). Twelve patients had synchronous disease and six patients developed metachronous
hepatic tumours over a median period of 20 months (range 6144). Presenting symptoms included abdominal pain (n
13), recurrent diarrhoea (n7) and flushing (n7). Fifteen patients underwent surgery with complete cytoreduction and
three patients had partial cytoreduction. The overall 2- and 5-year actuarial survival rates were 94% and 86%,
respectively. The 2- and 5-year disease-free rates following hepatic resection with complete cytoreduction were both 66%.
Partial or complete control of endocrine-related symptoms was achieved in all patients with functioning tumours following
surgery. Recurrent disease occurred in four patients following complete cytoreductive surgery. Resection margin
involvement was associated with developing recurrent disease (p0.041). Conclusion. Surgical resection for hepatic
NET metastases results in good long-term survival in selected patients and resection margin involvement was associated
with recurrent disease.
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Introduction
Hepatic metastases may develop in 5095% of
patients with neuroendocrine tumours (NETs) and
80% of patients with advanced hepatic involvement
will die within 5 years of presentation [1,2]. Hepatic
NET metastases may give rise to symptoms due to
tumour mass effect or secretion of polypeptide
products with specific hormonal activity [3]. Due to
the relatively slow growth rate of NETs and poor
long-term prognosis, the appropriate treatment for
hepatic NET metastases remains a challenge.
Treatment modalities for hepatic metastases from
NETs include resection, radiofrequency ablation
(RFA), somatostatin analogue therapy, arterial embo-
lization, liver transplantation and, in selected cases,
administration of interferon-alpha or systemic chemo-
therapy. The 5-year survival of patients given only
medical treatment is poor, around 2040% [4,5].
High recurrence rates up to 67% have been reported
following orthotopic liver transplantation for hepatic
NET metastases [612]. Arterial embolization has
been shown to palliate symptoms by reducing both
tumour size and hormone production [1317]. Stu-
dies have shown that surgical resection in selected
patients with hepatic NET metastasis can obtain
resolution of endocrine-related symptoms and in-
crease survival [10,1823].
The aims of the current study were to evaluate
the clinical outcome of patients following surgical
resection for hepatic metastases from NET and
identify clinico-pathological predictors of recurrent
disease.
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Patients and methods
Patients
Patients referred with hepatic metastasis from NET to
the Hepatobiliary Unit, St James’s University Hospi-
tal (SJUH), Leeds, UK, during the 13-year period
from January 1994 to December 2006, were identified
from a prospectively maintained hepatobiliary data-
base. The medical records of patients were retro-
spectively reviewed for demography, clinical and
treatment data. Biochemical analysis [liver function
tests (LFTs)  alkaline phosphatase, alanine amino-
transferase and bilirubin] and urinary 5-hydroxyin-
dole acetic acid (HIAA) levels at presentation were
collated. Preoperative radiological assessment in-
cluded thoracic, abdomen and pelvis computed to-
mography (CT) and magnetic resonance imaging
(MRI) of the liver. When appropriate, in selected
cases isotope bone scan, somatostatin receptor scinti-
graphic scanning (octreoscan) and echocardiogram
were performed.
Surgery and follow-up
Surgical resection was classified as complete and
partial cytoreduction resection. Surgical resection
with complete cytoreduction involved the complete
resection of all tumours identified at operation,
including the primary tumour, hepatic metastases
and other intra-abdominal disease. Partial cytoreduc-
tion surgery was defined when resection of all
tumours was not feasible. Hepatic resection was
performed using the Cavi-Pulse Ultrasonic Surgical
Aspirator (CUSA, Model 200T, Valley Lab., Color-
ado, USA). Intraoperative ultrasound was performed
to confirm the findings of preoperative imaging and to
assist in surgical planning.
Following initial postoperative review at 1 month,
all patients were examined in the outpatient clinic at
3, 6, 12, 18 and 24 months and annually thereafter. At
3, 6, 12, 18 months, 2 years and annually thereafter
CT of chest, abdomen and pelvis was performed.
Liver MRI was used to define suspicious lesions
demonstrated on CT or in cases of negative CT with
recurrence of endocrine-related symptoms.
Clinico-pathological characteristics
Histopathological data of the primary tumour and
metastases were analysed. Patients were considered to
have incidental hepatic metastasis if the lesion was
discovered during a work-up for a different medical
problem.
Statistical analysis
Non-parametric data are presented as median
(range), and categorical data as both frequency and
proportion (%). Univariable analysis was performed
to assess for a difference in clinico-pathological
characteristics between patients with recurrent disease
and patients who were disease-free following complete
cytoreduction surgery. The KaplanMeier method
was used to assess the actuarial survival and disease
recurrence rate. All statistical analysis was performed
using the Statistical Package for the Social Sciences
for WindowsTM version 14.0 (SPSS Inc., Chicago,
IL, USA), and statistical significance was defined as
pB0.05.
Results
Demographics
During the study period, 18 of the 82 patients with
hepatic metastases from NETs underwent surgery.
The median age at diagnosis was 53 (3175) years
and there were equal numbers of male and female
patients.
The localization of the primary tumour was the
terminal ileum (n8), pancreas (n7), appendix
(n2) or duodenum (n1). Twelve patients had
liver metastases at presentation, while the remaining
six patients developed metachronous hepatic tu-
mours. The median time interval between resection
of the primary tumour and detection of hepatic
metastases in these six cases was 20 (6144) months.
Presentation
Frequently reported symptoms at presentation were
abdominal pain (n13), recurrent diarrhoea (n7)
and flushing (n7). Other presenting symptoms
included weight loss (n3), palpitations (n2) and
jaundice (n1). Eight patients had functioning
NETs. Hepatic metastases were identified incidentally
in one patient. Abnormality in one or more preopera-
tive LFTs was recorded in four patients and urinary
HIAA levels were raised in eight patients.
Surgery
Fifteen patients underwent complete cytoreduction
surgery, which consisted of right hepatic trisectionect-
omy (n7, two cases having additional contralateral
non-anatomical resection), left hepatic trisectionect-
omy with caudate lobectomy (n1), right hemi-
hepatectomy with contralateral non-anatomical resec-
tion (n2), left hemi-hepatectomy (n1), segment
6 resection (n1) and non-anatomical resection (n
3). Partial cytoreduction resection was indicated in
three cases due to progression of endocrine-related
symptoms resistant to medical therapy, which in-
cluded a left lateral sectionectomy with non-anatomi-
cal resection and RFA (n1) and non-anatomical
resection (n2, one case having additional RFA).
Partial or complete control of endocrine-related
346 D. Gomez et al.
symptoms was achieved in all patients who underwent
hepatic resection.
The overall morbidity was 22%: postoperative
bleeding (n2), wound infection (n1), large bowel
perforation (n1). There was one death following
postoperative myocardial infarction. The median
follow-up period was 45 (993) months.
Histology analyses
Multiple hepatic metastases were present in 12
patients and 6 patients had a solitary hepatic metas-
tasis. Overall, the median number of hepatic metas-
tases was 3 (113) and the median size of hepatic
metastatic tumours was 4 (0.718) cm (Table I). Four
patients had evidence of tumour involvement on the
resection margin following complete cytoreduction
resection.
Outcome and prognostic factors associated with disease
recurrence
The overall 2- and 5-year actuarial survival rates were
94% and 86%, respectively (Figure 1). The overall
recurrence rate at 5 years was 34%. Recurrent disease
within the remnant liver following complete cytore-
duction occurred in four patients, with one patient
developing recurrence in the primary site (pancreatic
remnant). The median disease-free interval was 10.5
(624) months. Two patients with recurrent disease
underwent further hepatic resection (alive at 51 and
68 months) and all four patients with recurrence were
managed with somatostatin therapy (n4), che-
motherapy (5-fluorouracil and cisplatin, n4) and
interferon-alpha (n2), with three patients currently
having stable disease.
All three patients who underwent partial cytoreduc-
tion surgery had initially good control of their endo-
crine-related symptoms. With disease progression,
these patients were managed with octreotide therapy
(n3), chemoembolization (cisplatin/lipiodol 20 mg/
20 ml) and RFA (n1).
Differences in clinico-pathological features of pa-
tients who developed recurrent disease are presented
in Table II. On univariate analysis, hepatic resection
margin involvement was associated with developing
recurrent disease (p0.041). The 5-year disease
recurrence rate following complete cytoreduction
surgery with a clear resection margin was 10%
compared with 75% in cases with involved resection
margin (p0.049, Figure 2).
Discussion
Hepatic metastases are common in patients with NET
and current accepted treatment modalities include
somatostatin analogues, arterial embolization and
surgery. In keeping with other centres, we have
reported on the efficacy of hepatic resection for the
treatment of other metastatic gastrointestinal tumours
such as colorectal cancer [2427] and gastrointestinal
stromal tumours [28] with good clinical outcomes.
Various centres have adopted this approach in the
treatment of hepatic metastases from NETs, mainly
due to the fact that patients with unresectable disease
have a poor 5-year survival rate [29]. Published
literature on patients who underwent complete cytor-
eduction surgery showed a 5-year survival rate of
6187% (Table III) [10,22,23,2933]. The present
series has a 5-year survival rate of 86%. Comparing
these results to patients with unresectable hepatic
disease who have a 5-year survival of 3040%
[32,34], surgical resection in patients with resectable
Table I. Pathological findings of patients with metastatic NET in this study.
Location of
primary tumour
Tumour
Type
Histological
differentiation
Size [largest hepatic
metastasis (cm)]
No. of hepatic
metastases
Hepatic resection
margin (mm)
Appendix Carcinoid Moderate 2.5 11 Involved
Ileum Carcinoid Moderate 1.5 13 Involved
Pancreas Islet cell Well 2.5 2 2.5
Pancreas Islet cell Well 4 7 3
Ileum Carcinoid Well 3 1 30
Pancreas Islet cell Well 18 1 30
Ileum Carcinoid Well 9.5 6 15
Duodenum Carcinoid Well 14 9 6.5
Ileum Carcinoid Moderate 8 1 10
Pancreas Islet cell Moderate to poor 8 9 Involved
Pancreas Islet cell Well 1.7 1 Involved
Ileum Carcinoid Well 4 7 20
Ileum Carcinoid Well 7 3 1
Pancreas Islet cell Well 1.8 1 2
Pancreas Islet cell Poor 0.7 1 6
Ileum Carcinoid Well 5 3 NA
Ileum Carcinoid Moderate 6 3 NA
Ileum Carcinoid Moderate 2.5 2 NA
Patients 115, curative intent; 1618, palliative resection; NA, not applicable as palliative resection.
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hepatic metastases may improve survival rates. In
addition, we have previously reported good results
following hepatic resection for primary hepatic NET
[35].
High recurrence rates up to 76% at 5 years
following hepatic resection have been reported in the
literature [10,22,23,2933]. The recurrence rate at 5
years in the present series is 34%, which is compar-
able to previous studies. In certain cases, recurrent
disease can be managed with re-resection, as per-
formed in two patients in this study who are currently
alive at 51 and 68 months since initial presentation. In
concordance with its natural history and high recur-
rence rates, hepatic metastases from NET could
indicate that systemic disease is already present and
therefore, aggressive resection cannot be considered
curative. Nevertheless, results from the present and
previous studies suggest that surgical resection should
be an accepted treatment modality in selected pa-
tients, as it increases survival rates and controls
endocrine-related symptoms.
To date, few prognostic factors for patients with
metastatic NET have been identified, mainly due to
the rarity of this disease. Chamberlain et al. demon-
strated that degree of hepatic involvement signifi-
cantly affected overall survival in the 34 patients that
underwent hepatic resection [29]. Size of hepatic
metastases, radicality of the surgical procedure and
localization of the primary tumour have also been
shown to affect survival [33]. Yao et al. found that
previous resection of the primary tumour and four or
less hepatic metastases had a significant impact on
Figure 1. Overall survival in patients with hepatic metastases from NET in this study. indicates patients who are alive.
Table II. Clinico-pathological characteristics of patients with metastatic NET who underwent resection with curative intent.
Clinical and pathological characteristics Disease-free (n10) Recurrent disease (n4) p value*
Demographics
Male: female ratio 5:5 1:3 0.580
Age at diagnosis [median (range) years] 53.5 (3175) 54.5 (4259) 1.000
Pathological analysis
Primary site 0.245
Pancreas 3 3
Gastrointestinal tract 7 1
Size of hepatic metastasis [median (range) cm] 4 (0.714) 2.5 (1.78) 0.523
No. of hepatic metastases [median (range)] 4.5 (113) 5.5 (111) 0.612
Synchronous hepatic metastasis 7 2 0.580
Histological differentiation 0.580
Well-differentiated 7 2
Moderately and poorly differentiated 3 2
Resection margin 0.041
Involved 1 3
Clear 9 1
*Statistical analysis was performed on 14 patients who had surgical resection of metastatic disease with curative intent (4 patients were
excluded from analysis; 1 patient with early postoperative death and 3 patients who had palliative surgery).
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disease-free survival following hepatic resection in 16
patients [31]. An elevated serum alkaline phosphatase
has been shown to be associated with a shorter
survival time in patients with hepatic NET metastases
[36]. In the present study, only the status of the
resection margin was a significant predictor of recur-
rent disease. Hence, although it may be important to
obtain a clear resection margin during surgery, this
may lead to extensive hepatic resection, which could
compromise postoperative liver function and limit
subsequent treatment options due to limited func-
tional liver remnant. In such cases, enucleation of
hepatic tumours is justifiable.
Somatostatin analogues, such as octreotide, are
used for the control of hormonally induced symptoms
and are believed to improve the quality of life in these
patients [37], and may also decrease the rate of
disease progression [38]. However, somatostatin ther-
apy rarely results in tumour regression and their
efficacy in controlling endocrine-related symptoms
tends to decline with disease progression [3945]. In
this particular disease process, hepatic resection is a
potential treatment modality for managing endocrine-
related symptoms. In a series of 108 patients with
endocrine-related symptoms, hepatic resection re-
sulted in a considerable degree of symptom control
in 96% of patients [30]. However, a high recurrence
rate of endocrine-related symptoms of 59% at 5 years
was documented in this study [30]. The groups of
Dousset [10] and Chamberlain [29] also found good
response to symptom control following debulking
palliative procedures. In the present study, there was
partial or complete response of hormonally induced
symptoms in all cases that underwent hepatic resec-
tion irrespective of intent. Two of the three patients
who underwent partial cytoreduction resection
for disease progression in this study are currently
alive at 60 and 72 months, respectively, with advanced
disease. Although limited by a small number of
patients, these results indicate that surgical resection,
Figure 2. Disease recurrence in patients with hepatic metastases from NET who underwent surgery with curative intent in this study with
respect to resection margin (RM) status.
Table III. Previous published series (1990 to present) of surgical resection with curative intent for hepatic metastases from NET.
Series
Study period
(year of publication) Centre
Sample size
(surgical resection) Survival rate Recurrence
Que et al. [23] 19841992 (1994) Rochester, USA 28 73% at 4 years 65% at 5 years
Dousset et al. [10] 19861994 (1996) Paris, France 17 87% at 5 years 64% at 5 years
Chen et al. [32] 19841995 (1998) Baltimore, USA 15 73% at 5 years 67% at 5 years
Chamberlain et al. [29] 19921998 (2000) New York, USA 34 76% at 5 years 66% at 5 years
Jaeck et al. [22] 19861998 (2001) Strasbourg, France 13 91% at 3 years 31% at 3 years
Nave et al. [33] 19831996 (2001) Hannover, Germany 10 86% at 5 years NS
Yao et al. [31] 19922000 (2001) Chicago, USA 16 70% at 5 years 31% at 5 years
Sarmiento et al. [30] 19771998 (2003) Rochester, USA 75 61% at 5 years 76% at 5 years
Present series 19932005 Leeds, UK 15 86% at 5 years 34% at 5 years
NS, not stated.
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irrespective of intent, may be considered in selected
patients as it may not only control endocrine-related
symptoms, but may also increase survival.
In summary, the present series demonstrates that
resection of hepatic metastases from NETs results in
good long-term survival in selected patients. Hence,
in cases where hepatic metastases appear resectable
on preoperative imaging, surgical resection should be
attempted. A clear resection margin was a predictor of
disease-free interval in the present study. Hepatic
resection is also a treatment option for managing
endocrine-related symptoms, especially in cases re-
sistant to medical therapy.
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